Alliance for Aging Research Provides Public Comment to the FDA About COVID-19 Vaccine Development and Administration
Published October 22, 2020
October 22nd, 2020 – On October 22, 2020, Alliance for Aging Research President and CEO Sue Peschin provided public comment to the U.S. Food and Drug Administration (FDA) and its Vaccines and Related Biological Products Advisory Committee (VRBPAC) about the Alliance’s position about vaccines to prevent COVID-19. In her comments, Sue emphasized the importance of:
- older adults taking FDA-approved enhanced (high-dose or adjuvanted) flu products to help protect them during flu season;
- the FDA understanding geriatric immune response as the agency reviews COVID-19 vaccines;
- transparency from the FDA, VRBPAC, and all vaccine sponsors about all steps being taken to ensure COVID-19 vaccines are safe and effective for older adults, particularly those 80 and older;
- taking into account how COVID-19 vaccines will be coadministered with flu or other CDC-recommended adult vaccines.
Read the full comment here.